These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19706807)

  • 1. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
    Chien AJ; Illi JA; Ko AH; Korn WM; Fong L; Chen LM; Kashani-Sabet M; Ryan CJ; Rosenberg JE; Dubey S; Small EJ; Jahan TM; Hylton NM; Yeh BM; Huang Y; Koch KM; Moasser MM
    Clin Cancer Res; 2009 Sep; 15(17):5569-75. PubMed ID: 19706807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
    Abu-Khalaf MM; Baumgart MA; Gettinger SN; Doddamane I; Tuck DP; Hou S; Chen N; Sullivan C; Lezon-Geyda K; Zelterman D; Hatzis C; Deshpande H; Digiovanna MP; Azodi M; Schwartz PE; Harris LN
    Cancer; 2015 Jun; 121(11):1817-26. PubMed ID: 25649370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
    Yardley DA; Hart L; Bosserman L; Salleh MN; Waterhouse DM; Hagan MK; Richards P; DeSilvio ML; Mahoney JM; Nagarwala Y
    Breast Cancer Res Treat; 2013 Jan; 137(2):457-64. PubMed ID: 23224144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
    Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
    Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
    Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
    Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W
    Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.
    Huang Y; Liang W; Yang Y; Zhao L; Zhao H; Wu X; Zhao Y; Zhang Y; Zhang L
    BMC Cancer; 2016 Jul; 16():464. PubMed ID: 27411683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
    Park IH; Lee KS; Kang HS; Kim SW; Lee S; Jung SY; Kwon Y; Shin KH; Ko K; Nam BH; Ro J
    Invest New Drugs; 2012 Oct; 30(5):1972-7. PubMed ID: 22006161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
    Tan AR; Dowlati A; Stein MN; Jones SF; Infante JR; Bendell J; Kane MP; Levinson KT; Suttle AB; Burris HA
    Br J Cancer; 2014 May; 110(11):2647-54. PubMed ID: 24800949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
    Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
    Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
    Burris HA; Taylor CW; Jones SF; Koch KM; Versola MJ; Arya N; Fleming RA; Smith DA; Pandite L; Spector N; Wilding G
    Clin Cancer Res; 2009 Nov; 15(21):6702-8. PubMed ID: 19825948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
    Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK
    Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
    Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
    Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Ramaswamy B; Bekaii-Saab T; Schaaf LJ; Lesinski GB; Lucas DM; Young DC; Ruppert AS; Byrd JC; Culler K; Wilkins D; Wright JJ; Grever MR; Shapiro CL
    Cancer Chemother Pharmacol; 2010 May; 66(1):151-8. PubMed ID: 19774377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.